Immunovant (IMVT) Common Equity (2018 - 2026)

Immunovant's Common Equity history runs 9 years deep, the most recent figure standing at $852.6 million for Q1 2026.

• Quarterly Common Equity rose 20.52% year-over-year to $852.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $852.6 million (up 20.52% YoY) and the FY2026 annual result came in at $852.6 million, up 20.52% from the prior year.
• Common Equity was $852.6 million for Q1 2026 at Immunovant, down from $986.1 million in the prior quarter.
• Across five years, Common Equity topped out at $986.1 million in Q4 2025 and bottomed at $251.8 million in Q3 2023.
• A 5-year average of $526.4 million and a median of $469.8 million in 2022 frame the typical range for Common Equity.
• Annual changes were most pronounced in 2024 — Common Equity tumbled 48.09% — and 2025, when it surged 179.66%.
• Immunovant's Common Equity stood at $414.7 million in 2022, then jumped by 63.82% to $679.3 million in 2023, then tumbled by 48.09% to $352.6 million in 2024, then jumped by 179.66% to $986.1 million in 2025, then fell by 13.54% to $852.6 million in 2026.
• Business Quant data shows IMVT's Common Equity at $852.6 million in Q1 2026, $986.1 million in Q4 2025, and $519.7 million in Q3 2025.